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Abstract 
Amino acid transporters of the SLC6 family mediate the Na+-dependent uptake of neutral amino 
acids into neurons and epithelial cells of the intestine, kidney and other organs. They are integral 
parts of amino acid homeostasis in the whole body and the brain. In the intestine they are involved 
in protein absorption, while in the kidney they regulate plasma amino acid concentrations through 
reabsorption. The metabolic role of SLC6 amino acid transporters in the brain is less clear and most 
likely related to anaplerosis of the TCA cycle. Mutations in these transporters cause rare inherited 
disorders such as Hartnup disorder and iminoglycinuria. They may also play a role in complex traits 
such as depression, anxiety, obesity, diabetes and cancer. The review does not cover the transport 
of neurotransmitter amino acids. 
Introduction  
The SLC6 family, also known as the neurotransmitter transporter family, is comprised of four 
branches. These are the GABA transporter branch, the monoamine transporter branch and the 
amino acid transporter branches (I) and (II) (Fig. 1) [1]. Transporters of the SLC6 family are involved 
in a variety of simple and complex disorders. This review will focus on diseases associated with 
general amino acid transporters and will also summarise features of mouse models of these 
transporters. It excludes diseases associated with the transport of the neurotransmitter glycine. 
Amino acid transporters of the SLC6 family are mainly expressed in two different types of cells: 
SLC6A7, SLC6A15, SLC6A16 and SLC6A17 are expressed in neurons, whereas SLC6A14, SLC6A18, 
SLC6A19 and SLC6A20 are expressed in epithelial cells. 
Structure of SLC6 amino acid transporters 
The structure of all transporters in the SLC6 family is closely related to the structure of the leucine 
transporter LeuT from Aquifex aeolicus [2]. LeuT is characterised by the presence of 12 
transmembrane helices, 10 of which form the core of the transporter. The 10 core helices are 
arranged in an inverted repeat fold, called the 5+5 inverted repeat (Fig. 2). In this repeat, helices 1-5 
and 6-10 are arranged in a pseudo two-fold symmetric pattern. This symmetry is thought to underlie 
the alternative access of substrates to the transporter [3]. LeuT has been crystallised in a 
conformation where the substrate is occluded in the center of the membrane, but where 
nevertheless a translocation pathway from the outside is clearly discernible [2]. Using mutations to 
destabilise the Na+-binding site 2 allowed crystallisation of LeuT in an inside-open conformation [4]. 
It is now thought that LeuT and structurally related transporters undergo a series of steps during the 
transport cycle [5] (Fig. 3). Initially, the substrate binding site is fully accessible from the outside 
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(open-out) (Fig. 3A). Once substrate and cosubstrates bind (Fig. 3B) they are occluded by small 
conformational changes of nearby residues (Fig. 3C). In the LeuT structure Phe253 interacts with the 
substrate and at the same time encloses it (occluded-out). The next step is a larger conformational 
change, following the symmetry of the inverted repeat, which results in a conformation that is fully 
occluded from both sides (Fig. 3D). This translocation is facilitated by interactions of the substrate 
and cosubstrates with the transporter. Subsequently the translocation pathway opens to the inside, 
but the substrate is still locked (occluded-in, Fig. 3E). Finally, small conformational changes of nearby 
residues including Phe259 allow release of the substrate and cosubstrates to the inside (open-in, Fig. 
3F). The empty transporter (Fig. 3G) can than change conformation back to the original state (Fig. 
3H). 
Small competitive inhibitors bind to the substrate binding site and are translocated, while more 
bulky competitive inhibitors bind to the substrate binding site, but cannot be enclosed thereby 
preventing transporter turnover. This is exemplified by the binding of tryptophan to LeuT, which 
results in an open-out conformation with tryptophan in the center of the membrane [6]. A second 
binding site in the outer vestibule has been identified in LeuT, but its role in substrate translocation 
or as an inhibitor binding site remains controversial [7, 8]. 
LeuT shows two binding sites for Na+-ions. The Na1-site is coordinated by the carboxyl-group of the 
substrate, side-chain oxygens of N27, T254 and N286, and backbone carbonyls of A22 and T254 
(Table 1) [2]. The Na2 site is coordinated by side-chain oxygens of T354 and S355 and backbone 
carbonyls of G20, V23 and A351.The secondary structure of helix 1 and 6 is interrupted in the center 
[2]. This allows backbone residues to make contact with the Na+-ions, instead of engaging in 
hydrogen-bonding within the α-helix. Comparison with other transporters of similar architecture 
suggests that the Na1-site is specific to the neurotransmitter transporter family, while the Na2-site 
also occurs in the glucose transporter vSGLT1 and the hydantoin transporter Mhp1 [9]. The critical 
residues involved in substrate and ion binding are found in helix 1, 3, 6, 7 and 8 [2]. 
When analysing the structure of LeuT in the two alternating access conformations it appears that 
helices 1,2,6 and 7 undergo significant conformational changes, while helices 3,4,5,8,9 and 10 are 
rather immobile [3]. The two groups of helices have been referred to as the hash (because of the 
arrangement of helices 3,4,8,9 in a # shape) and the bundle (helices 1,2,6,7) [10]. The movement of 
the bundle against the hash scaffold allows the movement of the substrate through the transporter. 
Helix 1, in particular bends around a hinge in the center of the helix, thereby allowing release of the 
substrate in the inside-open conformation [4].The precise making and breaking of bonds during this 
conformational change is unclear, but it is thought to involve interactions between Arg5 (TM1), Arg 
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30 (TM1), Ser267 (TM6), Tyr268 (TM6), Asp369 (TM8) and Asp404 (TM10). In particular the charge 
pair between Arg5 (bundle) and Asp369 (hash) on the intracellular side, must be broken to allow 
access from the inside. This energy could be balanced by the formation of a similar charge pair, 
involving Arg 30 (bundle) and Asp404 (hash) on the outside (Fig. 3). It is assumed that helix 11 and 
12 would be part of the scaffold. The sequence similarity of the mammalian SLC6 transporters to 
LeuT is high enough to align the residues of helix 1-10 with good precision. This allows the 
generation of homology models, which are thought to be quite reliable in the transmembrane 
domains [11, 12] (Table 1). The larger loops and helices 11 and 12, by contrast, cannot be modelled 
with similar precision. 
Substrate transport in mammalian SLC6 transporters is frequently Cl--dependent. The LeuT structure 
contains a peripheral chloride ion, which is unlikely to be of functional relevance [2]. Comparison of 
mammalian homology structures with the LeuT structure, however, revealed a buried glutamate 
residue (E290), which was replaced by a neutral residue in the mammalian transporter [11, 12]. In 
addition there was a cavity in the homology structures, which was flanked by residues that would 
allow Cl- binding. Subsequent structure-function studies revealed that this site is the functional 
chloride binding site in mammalian SLC6 transporters.  
The LeuT structure and its proposed different conformations thus provide a framework for the 
analysis of structure-function studies and for the analysis of mutations occurring in rare diseases. 
Residues critical for the function of LeuT and their homologues in the SLC6 amino acid transporters 
are listed in table 1. 
In the following, individual transporters will be described in more detail including their role in human 
disorders. The common name will be used when referring to the transport protein, the SLC 
nomenclature will be used when referring to the gene. The transporters are subdivided into two 
groups: (i) epithelial amino acid transporters affecting whole body homeostasis and (ii) brain amino 
acid transporters affecting brain metabolism. 
SLC6A14 (alias ATB0,+) 
Cloning and distribution: ATB0,+ was identified by database screening as a novel member of the SLC6 
family [13]. The transporter is expressed in the lung, salivary gland, mammary gland, stomach, 
pituitary gland, eye and colon. In the colon, lung and retina pigment epithelium the transporter is 
localised to the luminal membrane of epithelial cells [14, 15].  
Biochemistry of ATB0,+: ATB0,+ transports all neutral and cationic amino acids, but has no affinity for 
anionic amino acids. Proline has a much lower affinity for the transporter than other amino acids. 
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The order of preference is 
Ile>Leu=Met=Phe=Trp>Val=Ser>Tyr=Ala=His=Gly=Cys=Lys=Arg>Asn=Thr>Gln>>Pro [13]. Similar to 
other members of the SLC6 family, it co-transports substrates together with 2Na+ and 1Cl-, although 
this has only be tested with neutral amino acids and may be different for cationic substrates. The 
physiological role of the transporter has not been fully resolved. It could be important in regulating 
bacterial growth in the colon and preventing bacterial growth in the lung [16]. ATB0,+ also has an 
important role in carnitine transport and has been implicated in regulating development of early 
embryos at the blastocyst stage [17, 18]. 
SLC6A14 and obesity: In Finnish and French populations an association between obesity and 
chromosomal region Xq22-24 was identified. The linkage was refined and found to be maximal for 
two SNPs in the 3’-UTR of the SLC6A14 gene [19-21]. The frequency of the obesity associated alleles 
was slightly higher in the obese cohort, suggesting that ATB0,+ plays only a relatively minor role as a 
factor in the development of obesity. Owing to its expression in the pituitary gland the transporter 
might be involved in appetite regulation. Alternatively, it could contribute to development of the 
embryo thereby contributing to the development of obesity later in life [17]. 
ATB0,+ and cancer: Due to its broad specificity ATB0,+ can provide cells with all essential amino acids. 
Accordingly, it is upregulated in cancers derived from tissues that express the transporter 
endogenously, such as colon cancer and cervical cancer [22, 23]. It is also upregulated in breast 
cancer cell lines that are estrogen receptor positive. Accordingly, the SLC6A14 promoter is 
responsive to estrogen receptor activation [24]. An inhibitor of ATB0,+α-methyl-DL-tryptophan 
reduces growth of tumor cells and their ability to form colonies [25]. Interestingly, α-methyl-DL-
tryptophan also inhibits the system L transporter LAT1, which has been implicated in cancer growth 
[26]. However, the inhibitor only inhibited cell growth in ATB0,+ over-expressing cancer cells and not 
in others, while all cell lines expressed LAT1 at similar levels. As a result α-methyl-DL-tryptophan has 
the potential to inhibit certain forms of cancer. 
SLC6A19 (alias B0AT1) 
Cloning and distribution: SLC6A19 was identified by screening open reading frames on chromosome 
5p15 for genes that might be involved in Hartnup disorder [27]. The transporter is expressed mainly 
in the kidney and intestine. In the intestine it mediates the uptake of neutral amino acids after 
protein and peptide hydrolysis, while in the kidney it serves as the major mechanism to reabsorb 
neutral amino acids (Fig. 4). Smaller amounts are found in the skin and pancreas. The transporter is 
located in the apical membrane of the S1 and S2 segments in the kidney proximal tubule [28, 29]. In 
the intestine expression increases along the crypt villus axis towards the tips. 
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Biochemistry of B0AT1: The SLC6A19 gene encodes a transporter for a broad (B) range of neutral (0) 
amino acids and was hence named B0AT1 [30, 31]. The protein cotransports amino acids together 
with 1Na+ in an electrogenic transport mechanism. There is no obvious binding order as indicated by 
a reciprocal influence of Na+-concentration on substrate binding and of substrate concentration on 
Na+-binding [32]. The voltage-sensitive step in the transport cycle appears to be the step where 
substrate and cosubstrate are translocated through the membrane [30]. In view of the structure of 
the SLC6 family this charge is most likely the positively charged amino group of the substrate amino 
acid, because the negatively charged carboxyl-group forms an ion pair with Na1. Branched-chain 
amino acids and methionine are the preferred substrates of the transporter being translocated with 
a Km of about 1 mM.  Smaller and more polar amino acids bind with lower affinity and are 
transported with Km-values of up to 5 mM. Histidine, proline and glycine are very weak substrates of 
the transporter.  B0AT1 expression at the cell surface requires coexpression of a trafficking subunit. 
In the kidney the type I transmembrane protein collectrin (TMEM27) binds to B0AT1 allowing surface 
expression [33, 34]. In the intestine this function is mediated by angiotensin converting enzyme 2 
(ACE2) [35, 36]. Purification of B0AT1 from renal BBMV and reconstitution in proteoliposomes has 
yielded functional transporter in the absence of collectrin, suggesting that the trafficking subunits 
are not required for catalytic activity [32]. This also indicates that the interaction between collectrin 
and B0AT1 is fairly weak although they can be co-immunoprecipitated. The transporter is sensitive to 
sulfhydryl-reactive agents, such as mersalyl and HgCl2. The CXXC motif Cys200-Cys203 has been 
proposed as the binding site for methylmercury and HgCl2, while Cys45 or Cys49 have been 
proposed as residues for mersalyl binding [32]. 
Human disorders associated with SLC6A19: Hartnup disorder (OMIM234500) is an autosomal 
recessive disorder occurring with a frequency of about 1:30,000 in European populations [37]. It 
affects neutral amino acid transport in kidney and intestine and potentially other tissues such as 
skin. The hallmark of the disorder is a constant neutral aminoaciduria [38]. In some individuals 
additional clinical symptoms can be observed, such as a photosensitive skin rash, cerebellar ataxia, 
diarrhoea and psychotic behaviour. These symptoms usually occur in younger individuals and 
disappear in adults. This is most likely related to the increased amount of protein required during 
growth. Most of the symptoms are thought to arise from tryptophan deficiency. There are two lines 
of evidence supporting this. First, tryptophan-ethyl ester, a lipid soluble tryptophan derivative, was 
found to alleviate most symptoms of Hartnup disorder [39]. Second, the skin rash, often described as 
pellagra-like, responds to niacin supplementation [40]. Pellagra is caused by niacin deficiency 
(referring to either nicotinamide or nicotinic acid).  In the human body about 1/60th of tryptophan is 
converted to NADH, the reminder is synthesized from niacin [41]. As a result tryptophan can 
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contribute more to NADH biosynthesis than niacin depending on the tryptophan content of the 
food. In Hartnup disorder the lack of tryptophan absorption would need to be replaced by niacin 
supplementation. Urine screening programs in Canada and Australia have shown that clinical 
symptoms are not developed by every individual with Hartnup disorder [37, 40].  
To date more than 20 mutations in SLC6A19 have been described in patients with Hartnup disorder 
(Table 2). All of these change the peptide sequence of the transporter, no regulatory mutation has 
been identified. Neither have mutations been identified in collectrin or ACE2 that lead to Hartnup 
disorder. The homology model of B0AT1 can shed light on the molecular mechanism of some of the 
mutations [42]. Mutation Arg57Cys for example affects the formation of the charge pair with 
Asp486, which is involved in the gating process. Mutation Gly66Arg affects a narrow turn between 
helix 1 and 2, which is incompatible with a bulky side-chain. Mutation Gly284Arg is located at the 
beginning of the unwound alpha-helical structure in helix 6, which is essential for providing contacts 
with substrate and ions. Mutations D173N and R240Q affect the interaction between the trafficking 
subunits and the transporter and thus may be involved in protein-protein interactions [43]. An 
inherited disease that indirectly leads to aminoaciduria is MODY3 (maturity onset diabetes of the 
young type 3). MODY3 is caused by mutations in the nuclear hepatic factor 1α (HNF1α) [44]. HNF1α 
in turn is a transcription factor that drives expression of collectrin in the kidney [45]. Thus mutations 
in HNF1α cause collectrin deficiency, which in turn causes B0AT1 deficiency in the kidney. Deletion of 
HNF1α in mice causes a number of symptoms including renal Fanconi syndrome [46], a general 
defect of proximal tubular reabsorption including amino acids. 
Mouse models of B0AT1 deficiency: Four mouse models have been created, which shed light on the 
physiology of B0AT1 deficiency: B0AT1-deficient mice [47], collectrin-deficient mice [33, 34], ACE2-
deficient mice [48] and hph2 mice [49]. B0AT1-deficient mice lack the transporter in any cell type. 
Mice nullizygous for collectrin will lack surface expression of B0AT1 in collectrin expressing tissues, 
most notably the kidney. ACE2 nullizygous mice will have a lack of B0AT1 expression in the intestine 
and possibly to some extent in the kidney. Lastly hph2 mice show a similar aminoaciduria as in 
Hartnup disorder, but the mutation is unknown. Mice nullizygous for B0AT1 replicate most features 
of Hartnup disorder [47]. The mice have highly elevated levels of most neutral amino acids in the 
urine. Adult mice are 10-20% smaller than heterozygous and wildtype littermates. In some mice 
dermatitis was observed. Experiments with inverted sections of mouse intestine and renal BBMV 
showed that for most neutral amino acids B0AT1 is the only transporter in the apical membrane. 
While B0AT1 is the only transporter for glutamine in the intestine an additional transport activity was 
found in the kidney.  B0AT1 mediates about 50% of proline uptake and 2/3 of glycine uptake in the 
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human kidney [50]. The residual proline uptake is mediated by the IMINO transporter (SLC6A20), the 
residual glycine uptake by B0AT3 (SLC6A18). Western blotting indicated signs of amino acid 
malnutrition in the intestine, as ascertained by down-regulation of the mTOR pathway and up-
regulation of the GCN2/ATF4 pathway. The latter pathway is switched on by unloaded tRNAs, which 
appears to occur despite the presence of basolateral transporters. The mice also showed signs of 
altered tight-junction permeability as indicated by reduced claudin2 and occludin expression. 
Surprisingly, the study revealed that mice nullizygous for B0AT1 have severe problems in controlling 
body weight on diets of different protein content. When adapted to a 20% protein diet, B0AT1 
deficient mice rapidly lost weight on both a 6% protein diet and a 40% protein diet. Significant fat 
loss was observed on the 40% protein diet, which is most likely caused by the reduced carbohydrate 
content in this diet. 
Collectrin-deficient mice show similar aminoaciduria as B0AT1-deficient mice, and also show reduced 
body weight [33, 51]. Insulin secretion is reduced in both B0AT1 and collectrin-deficient mice. In 
collectrin-deficient mice this has been attributed to the interaction of collectrin with vesicular SNARE 
proteins, such as snapin, which regulate fusion of insulin-containing vesicles with the plasma 
membrane [45, 52]. However, it is less clear how this would occur in B0AT1-deficient mice unless the 
transporter is also expressed in β-cells. Both B0AT1 and B0AT3 require collectrin as a trafficking 
subunit to reach the apical membrane in the kidney [29, 48]. As a result it is expected that glycinuria 
is more prominent in collectrin-deficient mice than in B0AT1-deficient mice. Fractional excretion 
reaches 81% in collectrin-deficient mice, but the fractional excretion in Hartnup mice is unknown. 
Collectrin is not expressed in enterocytes, where this function is mediated by ACE2. ACE2-deficient 
mice do not show aminoaciduria consistent with a very marginal overlap of ACE2 and B0AT1 
expression in the kidney, but have a number of additional symptoms caused by the lack of ACE2 
activity [35, 48]. 
HPH2 mice were created by random ENU mutagenesis combined with urine screening in an attempt 
to identify the gene for Hartnup disorder [53]. The mutation was mapped to a locus on chromosome 
7, close to the gene of fibroblast growth factor 3. Interestingly, there is no obvious candidate gene 
within 0.8 cM of fgf3.  
SLC6A18 (alias XT2, XTRP2, ROSIT, B0AT3) 
Cloning and distribution: The B0AT3 transporter is closely related to B0AT1 [1]. The genes encoding 
both transporters are next to each other on chromosome 5 in humans and share significant 
sequence homology. B0AT3 was identified by homology cloning of SLC6 transporters from the kidney 
[54]. Initial studies failed to express the transporter functionally. In mouse the transporter is 
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expressed in six splice variants, many of which are severely truncated and unlikely to be functional 
[54]. While B0AT1 is expressed in both kidney and intestine, B0AT3 is largely confined to the kidney.  
Under normal conditions the transporter is expressed in the cortex, more precisely the S3 segment 
of the proximal tubule [28, 29]. Hypernatremic conditions cause strong up-regulation in both cortex 
and the outer medulla [55], while ischemia causes downregulation [56]. 
Biochemistry of B0AT3: B0AT3, like B0AT1 requires ACE2 or collectrin for surface expression, 
explaining the failure to express the transporter functionally in earlier studies [29, 48]. The first 
coexpression experiments suggested that only ACE2 could promote migration of B0AT3 to the cell 
surface [48]. This was surprising given that ACE2 expression in the proximal tubule is limited, while 
collectrin expression is strong. Subsequently, it was shown that both ACE2 and collectrin support 
surface expression [29]. In the presence of collectrin or ACE2 the transporter can be characterised in 
heterologous expression systems. Glycine and alanine are the main substrates of the transporter 
although it also mediates the uptake of a variety of neutral amino acids, particularly branched-chain 
amino acids and methionine. The transporter is both Na+- and Cl- -dependent. There is an apparent 
discrepancy between two studies with regard to the electrogenicity of the transporter. Singer et al., 
[48] reported the transporter to be electroneutral, while Vanslambrouck et al. [29] showed it to be 
electrogenic. In contrast to B0AT1 and B0AT2, B0AT3 is not pH-dependent. It is tempting to speculate 
that the Cl- -binding site in the former transporters is occupied by a OH- ion, which is not 
translocated. At acidic pH, the transporter loses activity due to lack of hydroxyl ions. Slightly 
different kinetic parameters were reported by the two groups. In the presence of collectrin the KM-
values for glycine and alanine were 2.3 mM and 0.9 mM, respectively. These amino acids induced 
the biggest currents in B0AT3 expressing oocytes. In the presence of ACE2 glycine was transported 
with a KM = 0.5 mM and isoleucine with a KM = 0.2 mM. The maximum velocity for isoleucine was 
twice as high as for glycine, whereas the opposite was observed in the case of collectrin.  
Mouse models of B0AT3 deficiency: In an attempt to understand B0AT3 function an SLC6A18 
nullizygous mouse was generated by Quan et al. [57]. The main phenotype was a three-fold 
increased glycine to creatinine ratio in the urine of B0AT3 deficient mice. Autoradiography confirmed 
reduced glycine uptake in the outer medulla. A high-affinity component of glycine transport was 
missing in brush-border membrane vesicles (BBMV) derived from kidney. The blood pressure of the 
mice was slightly elevated. In a subsequent study SLC6A18-nullizygous mice were fully back-crossed 
to the C57BL/6J background [48]. Urine analysis of these mice showed increased fractional excretion 
of Gly (51%), Met (33%), Leu (12%) and His (10%); values in parentheses indicate the amount of 
filtered blood appearing in the urine. ACE2-deficient mice have no increased fractional excretion. 
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Transport studies in renal BBMV derived from B0AT1-deficient mice, suggested that B0AT3 has a 
significant contribution to glycine transport, but not to leucine transport [47]. 
Human diseases associated with B0AT3: In humans glycinuria (OMIM 138500) and iminoglycinuria 
(IG, OMIM 242600) have been reported [50, 58]. Both are rare inherited disorders that seem to be 
caused by a combination of different alleles [59] (Table 3). In some pedigrees, glycinuria appears to 
be caused by haploinsufficiency of a major allele that in homozygosity causes iminoglycinuria (i.e. 
glycinuria caused by a mutation on one chromosome, iminoglycinuria cause by mutations in both 
chromosomes). In other cases glycinuria appears to be caused by separate alleles. In mice lack of 
B0AT3 causes glycinuria and alaninuria, consistent with the preference of the transporter [48]. In 
humans this does not seem to be the case, because a stop codon (Y319X) in SLC6A18 occurs in about 
40% of the population [60]. As a result 16% of the population are expected to be homozygous for 
this mutation, far more than the reported incidence frequency of glycinuria [61]. In a recent study on 
iminoglycinuria one individual in a cohort of 29 persons had a homozygous stop codon in the 
presence of normal alleles for all other proline and glycine transporters [50]. The urine amino acid 
levels were found to be normal. In human kidney the bulk of glycine is transported by the proton-
amino acid symporter PAT2 and the general neutral amino acid transporter B0AT1 [50] (Fig. 4). 
Haploinsufficiency of PAT2 causes glycinuria and thus is considered to be the major cause of 
glycinuria in humans [50].  
Both B0AT1 andB0AT3 have been implicated in hypertension in line with the phenotype observed in 
Slc6a18-nullizygousmice [57]. However, in a subsequent study differences in blood pressure were 
only found under stress-inducing conditions [48]. In a cohort of 1004 Japanese individuals no 
evidence for elevated blood pressure was found and this lack of association was also confirmed for 
the Korean population [60, 62]. A recent study reported the association of a specific microsatellite 
marker in the SLC6A19 gene with essential hypertension [63]. The underlying physiology is unclear as 
other microsatellites in the SLC6A19 gene did not show this association. Currently, there is no 
convincing mechanism linking blood pressure regulation to neutral amino acid transport in the 
kidney [64]. 
SLC6A20 (IMINO, XTRP3, XT3, SIT1, rb21a) 
Cloning and distribution: SLC6A20 was initially identified as a novel member of the SLC6 family [54, 
65]. Initial attempts to reveal its function were unsuccessful. After the identification of the amino 
acid transporter (II) family, two independent studies demonstrated that SLC6A20 encodes the 
system IMINO transporter [66, 67]. In mouse and rat two genes are found at the SLC6A20 locus, 
while only one gene remains in humans [1]. These are now referred to as SLC6A20a (IMINOa) and 
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SLC6A20b (IMINOb). Only IMINOa carries out active transport, IMINOb appears to be non-functional 
[67]. The IMINOa mRNA and protein is found in the brain and in the kidney, while IMINOb is found in 
the kidney only. In the brain the transporter is expressed in the choroid plexus and the pia mater 
[66, 67]. In the kidney the transporter is expressed throughout the proximal tubule, but expression 
increases towards the S3 segment. In the developing mouse embryo it is upregulated a few hours 
after fertilisation remaining high until the 2-cell stage [68]. During this time the transporter 
accumulates and retains betaine, which is known to improve development of preimplantation 
embryos. Expression of SLC6A20 is also developmentally regulated in newborn mice and humans 
[29]. Newborn humans show iminoglycinuria, which recedes after about 3 months. This is caused by 
an increased expression of SLC6A20 and of the proline/glycine transporter PAT2 (SLC36A2). 
Newborn mice have a more general aminoaciduria, which is remediated by increasing expression of 
SLC6A18, SLC6A19 and SLC6A20 in the first three weeks. Collectrin expression also increases over 
the same period.   
Biochemistry of IMINO: System Imino is a 2Na+ and Cl—proline cotransporter (KM = 0.13 mM) [66, 
67]. In addition it also transports the physiological substrates hydroxyproline (KM = 0.19 mM), 
betaine (KM = 0.2 mM) and sarcosine (KM= 3.2 mM) and the amino acid analogues MeAIB, pipecolic 
acid (KM = 0.09 mM), nipecotic acid (KM = 2.8 mM). The transporter is weakly stereospecific. The K0.5 
for Na+ is 22 mM, chloride binds with higher affinity (K0.5 = 2 mM). The chloride dependence can be 
rationalised by the presence of a conserved chloride binding site close to the Na1 binding site [69] 
(Table 1). When expressed in oocytes the transporter induces a leak current, the physiological role of 
which is unknown [69]. The Na+-affinity increases with increasing membrane potential consistent 
with the Na+-binding site being buried in the center of the transporter. 
Human diseases associated with SLC6A20:  Iminoglycinuria (IG, OMIM 242600) is a rare disorder 
associated with increased secretion of glycine, proline and hydroxyproline in the urine [59]. The 
condition is benign but has helped to understand amino acid reabsorption in the kidney. 
Developmental IG is a normal phenomenon in humans, dogs and rodents, whereby newborns 
release increased amounts of proline, hydroxyproline and glycine into the urine [70]. In humans 
prolinuria ceases after about 3 months, while glycinuria persists up to 6 months. Proline and glycine 
reabsorption is species specific, which has caused confusion in the interpretation of data [42]. In 
humans the main transporter for proline and glycine is the proton amino acid transporter PAT2 
(SLC36A2). Complete inactivation of this transporter by a homozygous mutation is sufficient to cause 
IG [50] (Table 3). PAT2 is not expressed in the intestine and therefore causes a purely renal 
iminoglycinuria. In addition IG can be caused by partially inactivating mutations of SLC36A2 in 
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combination with mutations in SLC6A20 (Table 3). This explains a known heterogeneity of IG, in 
which some individuals do have intestinal malabsorption of proline, while others do not [59]. In the 
mutated IMINO transporter Thr199 is replaced by methionine [69]. There are numerous additional 
non-synonymous SNPs in SLC6A20, which have not been functionally assessed. The combined 
PAT2/IMINO cases have reduced uptake of proline in the intestine due to reduced activity of the 
IMINO transporter. In mice proline and glycine transport is mediated by B0AT3 and IMINO, while 
PAT2 expression is minimal [29]. In fact PAT2 activity cannot be observed in mouse renal BBMV. 
Thus it appears PAT2 has replaced B0AT3 in humans.   
SLC6A20 and diabetes:  In the urine of rhesus macaques with early signs of type 2 diabetes elevated 
levels of pipecolic acid, glycine betaine and proline were detected [71]. These metabolites are 
substrates of IMINO and were also been found in the db/db mouse model of type 2 diabetes and in 
humans. The increased metabolite levels were paralleled by a reduced level of IMINO in the kidney 
of macaques and mice.  Other transporters such as SLC36A1 and the trafficking subunit collectrin 
were unaffected, suggesting that the reduction was not caused by general proximal tubular 
degeneration. As a result IMINO substrates may serve as an early indicator of type 2 diabetes in 
humans. 
SLC6A15 (alias v7-3, B0AT2) 
Cloning and localisation: The B0AT2 transporter was cloned from mouse brain, showing widespread 
expression in neurons across the cerebral cortex, hippocampus, cerebellum, midbrain and olfactory 
bulb [72, 73]. The mRNA for the transporter was detected in a variety of neurons, such as 
dopaminergic neurons in the substantia nigra, serotonergic neurons in the raphe nuclei, 
noradrenergic neurons in the locus coeruleus, glutamatergic neurons in the hippocampus and the 
olfactory bulb and cholinergic motor neurons [73, 74].  B0AT2 is expressed at the plasma membrane, 
while its closest homologue NTT4 has a similar tissue and cellular distribution, but resides largely on 
vesicular compartments [74, 75] (Fig. 5). Outside the brain the transporter is found in the lung and 
kidney in relatively small amounts. 
Biochemistry of B0AT2: B0AT2 is a neutral amino acid transporter preferring branched-chain neutral 
amino acids and proline. At saturating concentrations (causing the transporter be at Vmax) the order 
of the transport-induced currents is Pro (KM=200 µM)>Cys = Ala (KM=670 µM) = Thr= Val = Ser = Met 
(KM=40 µM) = Ile (KM=58 µM) =Leu (KM=81 µM) >Asn>Phe (KM=1 mM) >Gln (KM=5.3 mM) [76, 77].The 
KM-values do not coincide with the order of the maximum currents, suggesting that Vmax and KM are 
determined by different aspects of the substrate. Substrate uptake is Na+- but not Cl- -dependent 
and electrogenic; 1 charge (Na+) per substrate is translocated. The transporter is strongly pH-
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dependent, being almost inactive at acidic pH, but is affected only by the extracellular pH. The 
substrate KM decreases when the Na+-concentration is increased and vice versa, suggesting that 
there is no strong preference in the binding order of substrate and cosubstrate [76, 77]. The 
interdependence of substrate and co-substrate affinity suggests that the Na1-binding site is 
functional in B0AT2. The proposed chloride binding site is not fully conserved (Ala309 instead of Ser, 
see Table 1), which is consistent with a lack of chloride dependence. One of the major functions of 
branched-chain amino acids in the brain is to serve as anaplerotic metabolites in neurons [78] and 
provide amino-groups for neurotransmitter biosynthesis [79] (Fig. 5). Neurotransmitter biosynthesis, 
particularly glutamate and GABA removes intermediates of the TCA cycle, which need to be 
replenished. Valine, threonine, isoleucine and methionine degradation generates succinyl-CoA, 
which can be converted toα-ketoglutarate. Neurons lack pyruvate carboxylase, which is the major 
anaplerotic enzyme in most cell types [80]. 
Human diseases associated with SLC6A15: Depression is caused largely by environmental factors, 
but the predisposition to succumb to environmental factors has a heritable component. For 
instance, a Leu255Met mutation in the serotonin transporter SLC6A4 has been associated with 
depression [81]. In a large genome-wide association study a SNP 287kb downstream of the SLC6A15 
gene was recently found to be associated with major depression [82]. The odds ratio for 
homozygous carriers of the risk allele was 1.42 in a cohort of more than 6000 individuals. Whether 
this region has any regulatory influence on SLC6A15 expression is unknown. Analysis of B0AT2 
expression levels in brain samples from individuals with temporal lobe epilepsy showed a correlation 
between the SNP rs1545843 and B0AT2 mRNA expression levels. Risk genotype carrier status was 
associated with slightly reduced transcript levels. Whether this reduction is sufficient to influence 
brain metabolism remains to be shown. 
Mouse model of B0AT2 deficiency:  B0AT2 deficient mice are viable and fertile and do not show any 
obvious phenotype [83].  The animals gain weight at the same rate as wildtype littermates. Posture, 
gait, reflexes and general behaviour are normal. Initial tests suggested reduced olfactory sensitivity 
in B0AT2 deficient mice, consistent with its high expression in the olfactory bulb, however, these 
results could not be repeated with a different cohort. To test for a role of B0AT2 in hippocampus and 
cerebellum, spatial memory and locomotor coordination was tested; without observing significant 
differences. Interestingly, mature female B0AT2-deficient mice could hold balance on a rotating rod 
for longer time, than wildtype control mice. The bulk of proline transport in brain synaptosomes 
appears to be mediated by the specific proline transporter PROT, while about 20% of proline uptake 
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capacity appeared to be mediated by B0AT2. Similarly, about 50% of Na+-dependent leucine uptake 
was abolished in B0AT2 deficient mice. 
In the same study that investigated the association of B0AT2 with major depression [82], it was also 
found that stress-susceptible mice had significantly reduced levels of B0AT2 mRNA compared to 
stress-resilient mice. These results are at variance with the results from B0AT2 deficient mice, which 
showed no difference to wildtype mice in anxiety assessment after induction of stress. 
SLC6A17 (alias NTT4, XT1) 
Cloning and distribution: The NTT4 transporter was initially identified as an unusual member of the 
neurotransmitter transporter family [72, 84, 85]. The main difference was an extended extracellular 
loop between helix 7 and 8.  In situ hybridisation  revealed that the distribution of NTT4 and B0AT2 
are largely overlapping [74]. The highest concentration of NTT4 mRNA was found in the olfactory 
bulb, cerebral cortex, hippocampus, habenular and pontine nuclei, and cerebellum, lower expression 
was widespread. NTT4 mRNA in general was more abundant than B0AT2 mRNA. NTT4 is expressed in 
neurons, such as pyramidal cells, granular cells, Purkinje cells and motor neurons. The cellular 
distribution largely follows glutamatergic pathways, but neurons using other neurotransmitters also 
express NTT4. Immunohistochemistry revealed that NTT4 is found in axon terminals of glutamatergic 
and some GABAergic neurons. In transfected cells and in neurons NTT4 is mainly expressed in 
synaptic vesicles [75]. The transporter is expressed highly during development, when protein 
synthesis is high [86, 87]. 
Biochemistry of NTT4: Two studies have investigated the functional properties of NTT4 in different 
expression systems, coming to slightly different conclusions. Zaia and Reimer [88] exchanged the 
carboxy-terminus of NTT4 with that of B0AT2, thereby achieving expression in the plasma membrane 
of HEK293 cells. Functional characterisation showed the transport to be similar to B0AT2. Preferred 
substrates were leucine (Ki=0.3 mM), methionine, proline (KM= 0.4 mM), cysteine, alanine and 
glutamine (KM= 5.2 mM). Transport was Na+-dependent (KM= 23 mM), but not Cl- -dependent and 
electrogenic. Uptake is pH-dependent and is barely detectable at pH 5.5. In transfected cells the 
wildtype transporter was largely located in intracellular compartments, but still induced a 2.4-fold 
increase of proline uptake. This suggests that a fraction of the transporters is located at the cell 
surface. Induction of exocytosis by ionomycin further increased the transport activity. Parra et al. 
[89], by contrast used vesicles from PC12 cells, which express NTT4 endogenously and compared 
vesicular transport to cells where NTT4 had been silenced. Preferred substrates determined by this 
method were leucine, glycine (KM=1.7 mM), proline (KM= 0.86 mM) and alanine. Further experiments 
used the increase of vesicular transport in transfected CHO cells. These results suggested that NTT4 
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is neither Na+-dependent nor Cl- -dependent [89]. Vesicular proline uptake was almost abolished in 
the presence of bafilomycin or the absence of ATP, both manipulations inhibiting the V-type ATPase, 
which acidifies vesicular compartments. Further experiments using nigericin and valinomycin 
suggested that the pH-gradient was more important as a driving force compared to the membrane 
potential. The discrepancy between the two studies is difficult to resolve. The structure of the SLC6-
type transporters suggests that an exchange of the carboxy-terminus is unlikely to affect ion binding 
in the transporter. In the study by Parra et al., significant background activity had to be subtracted in 
all experiments, while there was significantly less background in the study by Zaia and Reimer. 
Sequence conservation also suggests functional Na+-binding sites to be present in NTT4 (Table 1). 
The lack of chloride dependence is consistent with a partially conserved Cl- binding site (A308 
instead of Thr). Overall it appears more likely that the transporter is Na+-dependent rather than H+-
dependent. The pH-dependence would render the transporter inactive on synaptic vesicles, whereas 
the study by Parra et al. suggests that the transporter is active in this compartment. 
There is no mouse model of NTT4 deficiency nor are there human mutations associated with the 
SLC6A17 gene. Three non-synonymous SNP’s are listed in the database 
(http://www.ncbi.nlm.nih.gov/snp): Ala57Thr/Pro; Val184Ile and Lys679Arg. These replacements are 
either conservative or do not occur in sensitive regions of the transporter.  
SLC6A16 (alias NTT5) 
Little is known about the physiology and biochemistry of NTT5. It was identified through database 
searches as a member of the SLC6 family [90]. It is mainly expressed in testis, and at lower levels in 
other peripheral organs such as lung, liver, prostate, pancreas and uterus. Expression of the myc-
tagged NTT5 in CHO cells suggested a predominantly intracellular/vesicular localisation. Attempts to 
express NTT5 in heterologous systems have been unsuccessful (unpublished data), as a result there 
are no functional data. Inspection of the critical residues involved in Na+-binding show that NTT5 has 
cysteine in position 125. The equivalent position in all other transporters is occupied by a conserved 
asparagine. 
There is no mouse model of NTT5 deficiency nor are there human mutations associated with the 
SLC6A16 gene. Four non-synonymous SNP’s are listed in the database 
(http://www.ncbi.nlm.nih.gov/snp): Ser108Arg; Phe233Val; Leu278Val; Arg459Gly. These 
replacements are either conservative and do not occur in sensitive regions of the transporter. 
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SLC6A7 (alias PROT) 
Cloning and distribution: The brain-specific proline transporter PROT was isolated by using 
degenerate primers to amplify conserved regions of SLC6 related genes. The transporter is strongly 
expressed in the cortex, hippocampus and midbrain, weaker in other areas [91]. More detailed 
investigation showed the transporter to be expressed in a subset of glutamatergic neurons, such as 
pyramidal cells of the cerebral, entorhinal and piriform cortex and mitral cells of the olfactory bulb 
[92]. In the hippocampus the transporter is found in the molecular layer of the dentate gyrus and 
specific layers of the CA1 and CA3 regions. The transporter is confined to synaptic vesicles in 
terminals apposing NMDA and AMPA receptors [93]. Exocytosis would then result in transient 
expression of the transporter in the presynaptic membrane. 
Biochemistry of PROT: The transporter is specific for L-proline (KM = 9.7 µM) and is inhibited by its 
analogues pipecolic acid (Ki = 14 µM) and sarcosine (Ki = 30 µM), but not by hydroxyproline, which 
discriminates it from IMINO [94]. Some amino acids such as phenylalanine and histidine inhibit the 
transporter, but do not seem to be substrates. The transporter is Na+- and Cl- -dependent, which are 
typical features of a plasma membrane transporter. The activity of the transporter on synaptic 
vesicles is unknown. Several high-affinity inhibitors of PROT have been identified namely enkephalin 
peptides (Ki between 0.2 µM and 5 µM), benztropin (Ki = 7.5 µM) and a compound called LP-403812 
(Ki = 0.12 µM) [95, 96]. 
The physiological role of PROT in the brain is unclear. Proline is a potent neuromodulator, which can 
potentiate glutamatergic neurotransmission in the hippocampus. Synaptosomes can synthesize 
glutamate from proline, but the synaptosomal localisation of the transporter is at variance with a 
role as precursor uptake mediator (Fig. 5). 
No mouse models or human diseases have been reported that could elucidate PROT function. 
Conclusion 
Sodium dependent amino acid transporters of the SLC6 family play an essential role in amino acid 
homeostasis in epithelial tissues and the brain. They provide building blocks for protein synthesis 
and serve as precursors for neurotransmitter metabolism. They regulate plasma amino acid levels 
and serve still unknown roles as metabolites in synaptic vesicles. Human diseases and mouse models 
illustrate these functions and lack of understanding prevails for transporters, where neither is 
known.  
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Figure legends: 
Figure 1: Dendrogram of the human SLC6 family. 
Reference peptide sequences of the human SLC6 family were aligned using T-coffee [97]. Distances 
were plotted as a dendrogram. The GABA transporter branch is highlighted in red, the monoamine 
transporter branch in orange, the amino acid transporter branch (I) in purple and the amino acid 
transporter branch (II) in green. 
Figure 2: Depiction of the 5+5 inverted repeat fold of the SLC6 family. 
(A) Transmembrane helices 1-10 of LeuT shown in blue (1-5) and yellow (6-10) to emphasize the 
inverted repeat fold. (B,C) Helices 1-5 were rotated to show the similarity of the two repeats. Helix 1 
and 6 can be identified by the interruption of the helix in the center. (D) The rotated repeats were 
merged to show the close overlap. Note the deviation between helix 1,2 and 6,7.   
Figure 3: Putative Transport cycle of SLC6 family transporters 
The transporter is open to the outside (A) allowing the substrate to bind (B). Binding of substrate 
causes small conformational changes of neighboring residues, which enclose the substrate (C). These 
changes trigger a large conformational change, which occludes the substrate in the center (D). 
Subsequently, the transporter opens to the inside, while the substrate is still enclosed (E). Small 
conformational changes of nearby residues (F) allow the release of the substrate (G). The 
transporter returns to its original conformation without substrate (H). Ionic interactions between 
mobile parts of the protein are important to facilitate the conformational change. 
Figure 4: Neutral amino acid transport in the kidney 
The bulk of neutral amino acids in mouse and human kidney is transported by B0AT1. Surface 
expression requires interaction with collectrin. In mouse kidney B0AT3 transports small neutral 
amino acids and IMINO transports proline. IMINO also requires collectrin for surface expression. In 
humans B0AT3 is mutated and its function is replaced by PAT2. Glycinuria in mice is caused by lack of 
B0AT3, while it is caused by PAT2 haploinsufficiency in humans. Iminoglycinuria is caused by lack of 
PAT2 or combined mutations in PAT2 and IMINO. 
Figure 5: The role of SLC6 amino acid transporters in the brain 
Branched-chain amino acids (BCAA) and proline are taken up into neurons by B0AT2. Proline can be 
converted to glutamate or is sequestered into synaptic vesicles by PROT and NTT4. Branched-chain 
amino acids are converted into TCA cycle intermediates or used to produce acetyl-CoA.  
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 Table 1: Residues involved in ion binding in the SLC6 amino acid transporters. 
Residues that could disrupt ion-binding site function are indicated in grey. Atoms involved in binding 
are shown in the last row. 
Transporter Na1 Na1 Na1 Na1 Na2 Na2 Na2 Na2 Na2 Cl Cl Cl Cl Cl 
LeuT A22 N27 T254 N286 G20 V23 A351 T354 S355 Y47 Q250 T254 N286 E290 
B0AT1 C49 N54 S278 N310 G47 V50 L427 S430 S431 F74 Q274 S278 N310 S314 
B0AT2 S78 N83 A309 N341 G76 V79 L470 G473 S474 Y103 Q305 A309 N341 S345 
B0AT3 A35 N40 S264 N296 G33 V36 L413 S416 T417 Y60 Q260 S264 N296 S300 
ATB0,+ A53 N58 S322 N354 G51 V54 L419 D422 S423 Y78 Q318 S322 N354 S358 
NTT4 S77 N82 A308 N340 G75 V78 L469 G472 S473 Y102 Q304 A308 N340 S344 
NTT5 S120 C125 N349 N381 G118 M121 M508 G511 S512 Y145 Q345 N349 N381 L385 
IMINO A22 N27 S251 N283 S20 V23 L402 G405 S406 Y47 Q247 S251 N283 S287 
PROT C54 N59 S298 N330 G52 V55 L395 D398 S399 Y79 Q294 S298 N330 S334 
Atom O Oδ O,Oγ Oδ O O O Oγ Oγ Oε-H Nε-H Oγ-H Nδ-H Oγ-H 
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Table 2: Mutations associated with Hartnup disorder 
Mutation (DNA) Mutation (protein) Frequency Reference 
Missense    
169C>T R57C n.r. [98] 
196G>A G66R <0.001 [99] 
205G>A A69T n.r. [36] 
277G>A G93R <0.001 [99] 
517G>A D173N 0.004-0.007 [100] 
532C>T R178X <0.001 [99] 
719G>A R240Q <0.001 [100] 
725T>C L242P n.r. [100] 
794C>T P265L n.r. [36] 
850G>A G284R <0.001 [99] 
908C>T S303L n.r. [101] 
982C>T R328C <0.001 [99] 
1213G>A E405K <0.001 [99] 
1501G>A E501K n.r. [100] 
1550A>G D517G <0.001 [99] 
1735C>T P579L n.r. [36] 
Nonsense    
682-683AC>TA T228X n.r. [98] 
718C>T R240X 0.001 [100] 
Deletions    
340delC L114fsX114 n.r. [98] 
c884_885delTG V295fsX351 n.r. [98] 
Insertions    
1787_1788insG Thr596fsX73 n.r. [101] 
Splice site    
IVS8 + 2G Aberrant splicing <0.01 [100] 
IVS11 + 1A Aberrant splicing n.r. [100] 
n.r.: not reported 
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Table 3: Mutations and polymorphisms associated with Iminoglycinuria (IG) and Glycinuria (G) 
Mutation 
(DNA) 
Gene Mutation 
(Protein) 
Frequency Reference Comment 
IVS1+1G>A SLC36A2 Protein 
truncation 
0.004 [50] IG (homozygous), 
G(heterozygous) 
260G>T SLC36A2 G87V 0.012 [50] IG in combination 
 with T199M 
596C>T SLC6A20 T199M 0.075 [50] IG in combination with 
G87V 
235G>A SLC6A18 G79S n.r. [50] Role unclear 
957C>G SLC6A18 Y318X 0.44 [50] Role unclear 
1433T>C SLC6A18 L478P 0.39 [50] Role unclear 
1486G>A SLC6A18 G496R 0.003 [50] Role unclear 
n.r.: not reported 
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